Skip to main content
Equibles
GLUE logo

GLUE · Monte Rosa Therapeutics, Inc. · Metrics

Track GLUE — free

Use GLUE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLUE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.05 -0.17 (-1.52%)
Russell 2000 member Rebalance outlook locked
Market Cap
$957.22M
Shares
85.31M
Volume · Oct 22 103.17K Avg daily vol (3M) 1.38M

GLUE metrics

80 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.22
Market cap
$957.22M

Price action

20 metrics
Price change (1W)
+14.0%
Price change (30D)
-11.0%
Price change (3M)
-52.8%
Price change (6M)
-46.5%
Price change (YTD)
-28.4%
Price change (1Y)
+17.0%
Trailing year
Price change (5Y)
-55.0%
52-week high
$25.31
52-week low
$9.35
Change from 52-week high
-55.7%
Change from 52-week low
+20.0%
Annualized volatility
82.9%
Annualized volatility (3M)
75.5%
Beta
1.1
RSI (14D)
48.0
Price vs SMA 50
-11.9%
Price vs SMA 200
-37.0%
Avg volume (3M)
1.38M
Relative volume
0.8
Average dollar volume
$19.31M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
85.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
30.2×
reciprocal yield 3.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
33.3×
reciprocal yield 3.0%
P / book
2.0
reciprocal yield 50.9%
FCF yield
-3.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.8×
reciprocal yield 7.2%
EV / revenue historical average (5Y)
13.8×
reciprocal yield 7.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-01-07

Profitability

9 metrics
Gross margin
—
Operating margin
-633.0%
Trailing 12 months
Net margin
-560.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$181.85M
Net income (TTM)
−$161.09M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-111.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.32
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.97
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.75
Operating cash flow per diluted share (TTM)
$-0.10
Free cash flow per diluted share (TTM)
$-0.18
Capital expenditures per diluted share (TTM)
$0.08
R&D per diluted share (TTM)
$1.85
Stock compensation per diluted share (TTM)
$0.22
Book value per share
$3.56

Growth

11 metrics
Revenue growth YoY
-61.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$28.73M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+23.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-33.1%
Return on assets
-23.3%
Debt / equity
0.0
Current ratio
10.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$32.08M
Quick ratio
10.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$90.10M
Latest balance sheet
Cash & equivalents
$90.10M
Total assets
$691.16M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$24.07M
Capital expenditures (TTM)
$8.01M
R&D (TTM)
$170.69M
SG&A (TTM)
—
Stock compensation (TTM)
$20.59M
R&D / revenue
594.2%
Stock compensation / revenue
71.7%

Ownership (13F)

9 metrics
13F filers
194
13F filer change QoQ
+2
Institutional ownership
109.3%
Conviction holders (share of 13F filers)
3.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.7%
Holder tenure
10.6
Price vs estimated holder cost
+80.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.1%

Short interest

3 metrics
Short interest
23.1%
Latest settlement · 18.0 days to cover
Days to cover
18.0d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$137
Insider-sentiment score
61 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 15 filings 15 filers Visit website Investor relations